
|Videos|September 9, 2021
Should anti-VEGF agents be used to treat patients with NPDR?
Author(s)OT Staff Reports
Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Jennifer Sun, MD, MPH, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Corza Medical announces launch of the SensorTek ROP Kit
2
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
3
EyePoint receives second consecutive positive recommendation from DSMC
4
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
5















































